Division of Urologic Surgery, University of North Carolina, Chapel Hill, NC, USA.
Ther Clin Risk Manag. 2008 Dec;4(6):1315-30. doi: 10.2147/tcrm.s3336.
The treatment for erectile dysfunction (ED) was revolutionized with the development of phosphodiesterase type 5 (PDE5) inhibitors. Tadalafil (Cialis((R)); Eli Lilly and Company, Indianapolis, IN, USA) is the newest and most versatile PDE5 inhibitor in the clinical armamentarium for the treatment of ED. Its most unique characteristic is its long half-life of 17.5 hours, which lends itself to a longer therapeutic window with on-demand dosing and effective steady-state plasma concentrations with once-daily dosing. Clinical trials have proven its safety and efficacy with both dosing strategies for all severities and etiologies of ED, including difficult-to-treat ED. This thorough review will discuss ED, the physiology of penile erection and the role of PDE5, and all aspects of tadalafil, from its development, through its pharmacology, to its latest clinical studies and indications.
治疗勃起功能障碍 (ED) 的方法随着磷酸二酯酶 5 (PDE5) 抑制剂的发展而发生了革命性变化。他达拉非（商品名：希爱力((R)); Eli Lilly and Company, Indianapolis, IN, USA）是临床治疗 ED 的 PDE5 抑制剂中最新和用途最广泛的一种。它最独特的特点是半衰期长达 17.5 小时，这使得按需给药具有更长的治疗窗口，并且每日一次给药可达到有效的稳定状态血浆浓度。临床试验已经证明，对于所有严重程度和病因的 ED，包括难治性 ED，这两种给药方案都具有安全性和有效性。这篇全面的综述将讨论 ED、阴茎勃起的生理学以及 PDE5 的作用，以及他达拉非的各个方面，从它的开发到它的药理学，再到它最新的临床研究和适应症。
